Abstract
Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have